In an infiltrative basal cell carcinoma with perineural invasion of a nerve greater than 0.1 mm, after re‑excision with clear margins, is adjuvant therapy required?

Adjuvant Therapy for Infiltrative BCC with Perineural Invasion >0.1 mm After Re-excision

Yes, adjuvant radiotherapy is strongly recommended for infiltrative basal cell carcinoma with perineural invasion of a nerve >0.1 mm, even after re-excision with clear margins.

Rationale for Adjuvant Radiotherapy

Perineural invasion (PNI) in BCC represents a high-risk feature that significantly increases the risk of local recurrence and morbidity through subclinical spread along nerve pathways 1. The presence of PNI, particularly when involving named nerves or nerves >0.1 mm in diameter, indicates aggressive tumor biology with potential for retrograde extension toward the skull base 1, 2.

Key Evidence Supporting Adjuvant Therapy

• Perineural invasion is definitively classified as a high-risk pathologic feature requiring adjuvant treatment across multiple tumor types, including head and neck malignancies where similar principles apply 1
• The ASCO guideline for salivary gland malignancy explicitly states that adjuvant radiation therapy should be offered to patients with perineural invasion, with coverage of the involved nerve(s) extending to the skull base with elective or intermediate doses (46-54 Gy) 1
• Infiltrative BCC subtype is inherently high-risk due to its growth pattern, which makes complete surgical clearance challenging even with negative margins 1, 2

Treatment Approach

Adjuvant Radiotherapy Specifications

• Target volume should include:

  • The surgical bed with appropriate margins 1
  • The involved nerve pathway extending proximally toward the skull base, even if not clinically involved 1
  • Elective coverage of the nerve tract with 46-54 Gy in conventional fractionation 1

• Radiation dose recommendations:

  • Minimum 60 Gy to the high-dose target (surgical bed) when conventionally fractionated 1
  • Lower doses (46-54 Gy) for elective nerve coverage 1

Why Clear Margins Are Insufficient

Even with histologically clear margins after re-excision, PNI creates a pathway for microscopic disease extension beyond what can be assessed surgically 1, 2. The infiltrative growth pattern compounds this risk by creating irregular tumor borders that may not be fully captured even with adequate surgical margins 1.

Critical Considerations

High-Risk Features Present

Your case has multiple high-risk features that mandate adjuvant therapy:

• Infiltrative histologic subtype (aggressive growth pattern) 1
• Perineural invasion of a nerve >0.1 mm (significant PNI) 1
• These features persist as risk factors regardless of margin status 1

Common Pitfalls to Avoid

• Do not assume clear surgical margins eliminate the need for adjuvant therapy when high-risk pathologic features like PNI are present 1
• Do not underestimate the significance of infiltrative subtype, which has high local recurrence rates even after complete excision 1, 2
• Do not delay radiotherapy while waiting for clinical evidence of recurrence, as PNI can result in deep extension that is difficult to salvage 1, 2

Multidisciplinary Discussion

This case should be reviewed by a multidisciplinary team including dermatologic surgery, radiation oncology, and potentially head and neck surgery if the anatomic location is complex 1. The presence of PNI >0.1 mm in infiltrative BCC represents an absolute indication for adjuvant radiotherapy based on extrapolation from head and neck cancer guidelines where this principle is well-established 1.

Alternative Only If Radiotherapy Contraindicated

If the patient has absolute contraindications to radiotherapy (e.g., genetic syndromes with radiation sensitivity, prior radiation to the same field), then very close clinical and imaging surveillance is the only alternative, though this is suboptimal 1. Consider MRI to evaluate for subclinical nerve involvement if radiotherapy is refused or contraindicated 1.